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Abstract
Background: HPV infects multiple sites in the epithelium, including the genitals and oral cavity. The relation between
genital and oral infections and serum antibodies can help explain the natural history and epidemiology of HPV.
Methods: We analyzed HPV data from NHANES derived from self-collected vaginal swabs (women ages 14–59,
2003–12), oral rinses (men and women 14–69, 2009–12), and serum (men and women 14-59, 2003–10).
Results: Type-concordance of cervicogenital and oral infections in women was found to vary widely by age.
Prevalence of oral infections with type-concordant antibodies was low but varied by sex: 0.2 % (95 % CI 0.0–0.8) for
women vs 0.8 % (95 % CI 0.4–1.3) for men. Vaccination was associated with a reduced risk of cervicogenital infection
for vaccine genotypes among ages 14–17 (0.2 (95 % CI 0.1–0.8)) and 18–24 (0.2 (95 % CI 0.1–0.3). Seroprevalence
trends in women showed a dramatic increase for recent birth cohorts, likely due to vaccination. By contrast, trends for
men remained relatively constant. Age-specific cervicogenital prevalence showed a consistent peak in the late teens
and twenties. Relative cervicogenital prevalence has largely been decreasing since the 1940–50 birth cohort.
Conclusions: There are complex patterns in HPV prevalence trends and type-concordance across infection sites and
serum antibodies. A multisite sampling scheme is needed to better understand the epidemiology and natural history
of HPV.
Keywords: Human papillomavirus, Prevalence, Type-concordant infection, NHANES, HPV vaccine, Age-Period-Cohort
modeling
Background
The human papillomavirus (HPV) infects multiple
mucosal sites in the epithelium and is the etiological agent
for over 90 % of anogenital cancers and an increasing
fraction of oropharyngeal cancers [1]. Although the pro-
gression from cervicogenital HPV infection to cancer has
been well documented because of access to tissue dur-
ing gynecological exams, very little is understood about
the progression to cancer in the head and neck. Indeed,
although testing for HPV at cervicogenital sites has been
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standard for some time, characterization of oral preva-
lence has only recently begun. Further, the association
between infection at different sites and their relation to
seroconversion is not well characterized. Ideally, a sin-
gle test, such as for seropositivity of certain HPV strains,
could act as a biomarker for the risk of genital and oropha-
ryngeal cancer [2].
There are many strains of HPV, and these are typically
classified according to their oncogenic risk. Genotypes
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 (Group 1)
are known to cause cancer, genotype 68 (Group 2A) prob-
ably causes cancer, and genotypes 26, 30, 34, 53, 66, 67, 69,
70, 73, 82, 85, 97 (Group 2B) are possibiliy carcinogenic
[3, 4]. HPV infection is associated with nearly every cervi-
cal cancer, 90 % of anal cancers, 60–90 % of some subsites
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of head and neck cancers, and 40 % of other genital can-
cers [1, 5]. HPV 16 causes about 70 % of genital cancers
and together 16 and 18 are responsible for 90 % [1]. HPV
6 and 11 cause 90 % of anogenital warts [1]. HPV 16 is
also found in 90 % of HPV-positive squamous cell carcino-
mas (SCCs) in the head and neck [6]. Most HPV infections
clear within a year or two [7–10], but some infections may
persist for decades and result in oncogenesis.
Vaccines have been developed to target certain strains of
HPV. Three vaccines are currently approved by the FDA:
GlaxoSmithKline Biologicals’s bivalent (16, 18) Cervarix,
and Merck’s quadrivalent (6, 11, 16, 18) Gardasil and
Merck’s nonavalent (6, 11, 16, 18, 31, 33, 45, 52, 58)
Gardasil 9 [11]. Vaccination against HPV is targeted at
females ages 11–12 but is recommended in the US for
both men and women with minimal sexual activity under
the age of 26 [12]. Vaccine coverage in the US has been
low, though increasing, especially among boys [13].
Few studies have thus far considered multiple-site con-
currence or type-concordance. Steinau et al. [14] reported
that, in the 2009–10 National Health and Nutrition
Examination Survey (NHANES), oral HPV infection was
five-fold higher in women ages 18–59 with a current cer-
vicogenital infection, and that type-specific concordance
was low. The Hawaii cohort study reported a relative risk
of 20.5 for acquiring a type-concordant anal infection after
a cervicogenital infection and a relative risk of 8.8 for
acquiring a type-concordant cervicogenital infection after
an anal infection [15]. Genital, anal, and serum data from
the HPV in Men (HIM) study paint a complicated picture
in which serum antibody levels and seroprevalence of cer-
tain HPV types are “higher in men with corresponding
anal HPV infection, regardless of genital coinfection, com-
pared with men with genital HPV infection alone” [16]
but that seroconversion rates were higher following gen-
tial infection than anal infection [17]. No seroconversion
was detected following oral infections, though the num-
ber of oral infections was too small (n = 3) to be especially
informative [17]. To our knowledge, no other studies have
been published considering seroconversion due to oral
infections.
Like many sexually transmitted diseases, prevalence of
HPV varies widely by demographic group in the US, pos-
sibly because of sexual assortativity and differences in
sexual behavior patterns. Genital prevalence among non-
Hispanic blacks, for instance, is significantly higher than
for non-Hispanic whites and Hispanics, and oral preva-
lence among non-Hispanic blacks and Hispanics is higher
than for non-Hispanic whites [14]. Further, prevalence
varies significantly with age. However, no attempt has yet
been made to disentangle the effects of age, birth cohort,
and time period for trends in HPV prevalence. One way
to differentiate these effects is by the use of age–period–
cohort (APC) models [18–21]. APC models have been
used for myriad public health issues including mortality
[22], smoking histories [23], and the incidence of several
cancers [24–29].
In this paper, we analyze three HPV outcomes: infec-
tion at cervicogenital sites (women only), infection at oral
sites (men and women), and presence of HPV antibod-
ies in serum (men and women), which is an indication
of either a previous infection at any site or of vaccina-
tion. We analyze associations between these outcomes
by demographic group and model temporal trends in
cervicogenital infections and seroprevalence in men and
women.
Methods
Data
The CDC’s National Center for Health Statistics (NCHS)
administers NHANES, a series of studies combin-
ing physical examinations in a mobile examination
center (MEC) and interviews (both in-home and audio-
assisted in-MEC) of a representative sample of the non-
institutionalized, civilian population of the US. Each
survey is conducted over a two-year period and is used
to assess the health and nutritional well-being of the US
[30]. Study design, weighting, and collection of samples
have been previously described [31–34]. The NHANES
survey 2003–12 was approved by the NCHS Research
Ethics Review Board (2003–04: protocol #98–12; 2005–
10: protocol #2005–06; 2011–12: protocol #2011–17), and
documented consent was obtained from all participants.
Self-collected vaginal swabs were analyzed for women
ages 14–59 in five NHANES iterations (2003–12) for 37
HPV genotypes, namely 6, 11, 16, 18, 26, 31, 33, 35, 39,
40, 42, 45, 51, 52, 53, 54, 55 (a subtype of 44), 56, 58,
59, 61, 62, 64 (a subtype of 34), 66, 67, 68, 69, 70, 71,
72, 73, 81, 82, 82 subtype IS39, 83, 84, and 89 (formerly
CP6108), with the Roche Linear Array. Serum samples
were collected and typed using Luminex Multiplex Assay
for HPV types 6, 11, 16, and 18 for both men and women
ages 14–59 for the same surveys, although the 2011–2012
data is not yet available. Oral rinses were administered
to both men and women ages 14–69 in the 2009–10 and
2011–12 surveys and tested for the above 37 genotypes
using PCR. The numbers of individuals sampled by demo-
graphic group are reported in Table 1. Restricted data
(ages 14–17) was accessed through agreement with the
NCHS Reseach Data Center. The analyses of this study
were approved by the University of Michigan Medical
School IRB (HUM00090326).
Statistical analysis
Statistical analyses were performed in SAS (version 9.2).
Estimates were made using two year MEC exam weights
[35]. We analyzed three HPV outcomes by demographic
group: infection at cervicogenital sites, infection at oral
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Table 1 Numbers of people conclusively tested for HPV or HPV antibodies at each site in the 2003–04, 2005–06, 2007–08, 2009–10, and 2011–12 National Health and Nutrition
Examination Surveys (NHANES)
Genital Serum Oral
Women Women Men Women Men
Demographic 03–04 05–06 07–08 09–10 11–12 03–04 05–06 07–08 09–10 03–04 05–06 07–08 09–10 09–10 11–12 09–10 11–12
All 1982 2168 2044 2209 2004 1706 2357 2101 2356 1586 2109 2084 2295 2755 2481 2747 2517
Race
Mexican American 459 532 432 472 227 366 608 438 505 341 542 438 517 583 275 606 313
Other Hispanic 62 78 269 248 212 65 86 289 261 56 71 252 234 329 275 295 236
White 844 861 810 950 637 797 927 846 1010 727 844 876 978 1150 762 1134 810
Black 543 591 461 403 571 416 617 440 423 387 568 412 432 517 720 563 692
Age
14–17 424 440 261 254 237 0 479 264 279 0 464 291 339 294 286 362 302
18–24 452 479 303 367 351 493 524 319 387 444 444 330 381 392 363 400 404
25–29 175 228 183 231 193 191 277 188 248 188 179 201 204 255 190 209 201
30–34 183 206 211 222 206 216 214 227 244 180 168 198 215 227 211 209 228
35–39 155 158 235 235 204 170 174 239 252 158 185 234 223 236 219 225 214
40–44 174 196 221 256 206 188 204 222 277 184 187 200 243 266 213 229 203
45–49 157 178 230 253 202 169 188 228 266 162 189 204 228 256 202 226 188
50–54 155 162 214 224 236 161 174 220 226 166 174 258 245 227 235 247 201
55–59 107 121 186 167 169 118 123 194 177 104 119 168 207 173 181 208 174
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sites, and presence of HPV 6, 11, 16, or 18 antibodies in
serum, which is a measure of cumulative exposure. For
each pair of outcomes, we also analyzed the weighted
proportion of individuals who were positive for the first
outcome and positive for the second with the same
HPV type (type-concordance). Analysis of cervicogenital–
oral concurrence—when one person has both oral and
cervicogenital infections, not necessarily of the same
genotype—is left to Additional file 1.
Survey participants self-identified asMexican American,
Other Hispanic, Non-Hispanic White, Non-Hispanic
Black, or Other Race - Including Multiracial (and, in
2011–12, Non-Hispanic Asian). Because of small sam-
ple sizes, we considered only the first four groups and,
where indicated, combined Mexican American and Other
Hispanic into one Hispanic category. In an effort to esti-
mate vaccine efficacy and avoid confounding, seropreva-
lence for women in 2007–08 and 2009–10 was analyzed by
vaccine status. Women reporting having had at least one
dose of an HPV vaccine were considered to be vaccinated.
Age–period–cohort modeling
Age–period–cohort (APC) models are epidemiologic
models used to disentangle effects of age, period (factors
affecting all people at a given time), and birth cohort (fac-
tors affecting all people born in a given time period) on
prevalence (e.g. HPV prevalence) or incidence (e.g. inci-
dence of oral cancer) [18–21, 23]. The traditional model
posits that incidence rates λ are described by a multiplica-
tive model with age (A), period (P), and birth cohort (C).
This is usually treated in the logarithmic form, in which
the following generalized linear model is fit:
log λ = β0 + βA(A) + βP(P) + βC(C). (1)
A model for prevalence P is
logit P = β0 + βA(A) + βP(P) + βC(C). (2)
We use this model formulation for genital HPV preva-
lence in women and prevalence of antibodies to types 6,
11, 16, or 18 inmen and women, all by race. One drawback
of APCmodels is their inherent unidentifiability: P = A+
C. In practice, the identifiability problem can be resolved
by considering only two-effects models, typically age–
period or age–cohort. In this study, age and cohort effects
are modeled using splines, using five degrees of free-
dom/knots for both age and cohort effects, corresponding
to one knot for every nine and eight years respectively.
The one excpetion is cohort effects for female genital
prevalence, where six knots were used, corresponding to
one every nine years. APCmodels were fit in the statistical
software R.
Results
Oral–cervicogenital concordance
Figure 1 presents stacked bar graphs of oral and
cervicogenital HPV prevalence for women who were
tested conclusively for both oral and cervicogenital HPV.
Because oral HPV infection is relatively rare among
women, we combine 2009–2010 and 2011–2012 data to
support the analysis by demographic group. Prevalence at
each site is broken into two categories: infections that are
not type-concordant and those that are.
The percentage of oral infections among women ages
14–59 that are type-concordant with a cervicogenital
infection is 33 % (1.1 % (95 % CI: 0.6–1.5) concordant
infection over 3.3 % (95 % CI: 2.5–4.1) oral infection), but
this varies dramatically with age. Concordance peaks at
18–24 (87 % concordant: 3.6 % (95 % CI: 1.6–5.6) over
4.1 % (95 % CI: 2.1–6.1)) and 45–49 (45 % concordant:
1.8 % (95 % CI: 0.0–3.8 %) over 4.0 % (95 % CI: 1.5–6.5)). In
contrast, the vast majority of cervicogenital infections are
unaccompanied by an oral infection of the same type: only
3 % of cervicogenital infections are accompanied by a con-
cordant oral infection (1.1 % (95 %CI: 0.6–1.5) concordant
infection over 39.1 % (95 % CI: 36.4–41.8) cervicogenital
infection).
In Fig. 2, we present the prevalence of genotypes in
2009–2012 among women who had (a) a cervicogeni-
tal infection, (b) an oral infection, (c) a type-concordant
infection, and (d) among men who had an oral infection.
Genotypes 16, 62, and 84 are common across all sites.
The high prevalence of HPV 44 among oral infections
may be indicative of a tropic preference for oral tissue.
The high prevalence of HPV 70 and HPV 83 among oral–
cervicogenital concordant infections appear to be driven
by birth-cohort differences: although neither is particu-
larly common among female oral infections when looking
the overall population, HPV 83 is the second most com-
mon HPV type among women ages 18–24 (after HPV
84), the group where most oral–cervicogenital concor-
dant infections are found, whereas HPV 70 is the third
most common type among women ages 45–49 (after HPV
44 and 62), the other age group with a large fraction of
concordant infections.
Serum antibodies and concordant infections
HPV serostatus (for types 6, 11, 16, and 18) by age and
race is presented as a stacked bar graph in Fig. 3, separated
by type-concordance with cervicogenital infections for
women. Here, type-concordance means that an antibody
serotype matches a cervicogenital genotype; this defini-
tion is a proxy for true serotype concordance because full
serotype profiles are not available. Prevalence of genital
infections is not available for men in this survey, and thus
type-concordance in men cannot be assessed. Prevalence
of type-concordance of types 6, 11, 16, and 18 among
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Fig. 1 Oral and cervicogenital HPV prevalence and type-concordance for women ages 14–59. Oral (a and b) and genital (c and d) prevalence are
given by age and race in 2009–10 and 2011–12 and are separated into type-concordant and non-type-concordant infections. Type-concordant
infections represent a simultaneous oral and cervicogenital infection of the same genotype
all women has remained around 10 % (2003–04: 10.4 %
(95 % CI: 7.8–14.3), 2005–06: 11.1 % (95 % CI: 8.1–15.0),
2007–08: 10.3 % (95 % CI: 7.9–13.6), 2009–10: 8.4 %
(95 % CI: 7.1–9.9)).
Oral HPV prevalence by age and race is presented as
stacked bar graphs in Fig. 4, with serotype-concordance,
for both men and women. Serotype-concordance is
defined as an oral infection of type 6, 11, 16, or 18
with serum antibodies of the same type. Prevalence of
serotype-concordant oral infections is very low overall
(men and women ages 14–59: 0.5 % (95 % CI: 0.2–0.8), and
almost nonexistent for women (0.2 % (95 % CI: 0.0–0.8)
vs 0.8 % (95 % CI: 0.4–1.3) for men). For men, this con-
cordance remains around 10 % of the total oral infection,
which varies with age; over all ages 14–59, concordance is
8.6 % of the oral prevalence (9.8 % (95 % CI: 7.9–11.7)).
Seroprevalence and vaccination
The sharp increase in seroprevalence over subsequent
surveys for 14–17 and 18–24 year old women in Fig. 3 is
of particular interest. We suggest that this is the impact of
vaccination. Vaccination, as expected, is associated with
seroconversion: in 2009–10, 97 % (95 % CI: 93–100) of
women ages 14–17 who reported at least one dose of vac-
cine were seropositive for type 6, 11, 16, or 18, as were
91 % (95 % CI: 85–97) of those aged 18–24.
We present seroprevalence for women in 2007–08 and
2009–10 as stacked bar graphs with vaccination status in
Fig. 5. The shaded portion of the bar gives the fraction of
those who are seropositive and also reported being vac-
cinated. The fraction of women who are seropositive and
unvaccinated (unshaded portion) in each age category is
roughly the same between 2007–08 and 2009–10, and the
large increase in seroprevalence among 14–17 and 18–24
year old women is seen to be the addition of vaccinated
people.
Cerivcogenital HPV prevalence was also analyzed by
vaccine status in 2009–12 (Table 2). Vaccination was asso-
ciated with significant reduction in risk for genital infec-
tion by genotypes 6, 11, 16, and 18 in the 14–17 and 18–24
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(c) Among women with type−concordant cervicogenital−oral infections (N=45; population prevalence 1.1%)
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(d) Among men with oral infections (N=767; population prevalence 10.6%)
Fig. 2 Genotype prevalence among those with HPV infections. For each category, we give the number positive for HPV, the population prevalence,
and the genotype prevalence among those who have HPV. Group 1 genotypes are in dark grey, Group 2 genotypes in medium grey, and all others
in light grey
age groups. Vaccination was not associated with either an
increase or decrease in risk for infection when considering
all genotypes. The data were insufficient to be conclusive
for the impact vaccination has on the risk of oral infection.
Age-period-cohort models
Age–cohort models fit the data better than age–period
models. Figure 6 shows age-specific prevalence (relative
to the 1980 birth cohort) and cohort-specific relative
prevalence (relative to 50 % prevalence; for other relative
prevalence, see Additional file 1) of APC models for cer-
vicogenital prevalence (women) and seroprevalence (men
and women) by race. Model fits of the data are avail-
able in Additional file 1. Here the Mexican American
and Other Hispanic race categories were collapsed to
Hispanic. The age-specific prevalence for Hispanic and
white females is similar to that of the overall trend:
peaking around age 25 and subsequently decreasing. For
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Fig. 3 HPV seroprevalence for women, with cervicogenital type-concordance, andmen, ages 14–59. Seroprevalence is for genotypes 6, 11, 16, and 18
between 2003–10 and is given (a) by age and (b) race for women and (c) by age and (d) by race for men. Type-concordance means that the antibody
serotype is 6, 11, 16, or, 18 and matches the genotype of a current cervicogenital infection. The four bars in each group are 2003–04, 2005–06,
2007–08, and 2009–10 respectively. Note: Data for 14–17 year old men and women not available in 2003–04, and race data excludes ages 14–17
black women, however, prevalence is 10–20 % greater
than the average. Prevalence for this demographic group
also peaks slightly later. For cohort effects, the relative
prevalence for all demographic groups has been decreas-
ing since the 1940s birth cohorts, although that of black
women has been increasing again since the 1980 birth
cohort.
Seroprevalence for women increases dramatically
between ages 20–30, after which it largely stays constant,
except for Hispanic women for whom it continues to
increase with age. For men, the trend is a more steady
increase over the lifetime. There are strong effects on
seroprevalence for birth cohorts after 1980 for women.
Excluding vaccinated women in the cervicogenital anal-
ysis does not substantially affect either the age or cohort
effects; excluding vaccinated women from the serum
analysis does not substantially affect the age effects but
does, as expected, significantly reduce the cohort effects
after 1980 (results not shown).
Discussion
The relatively low oral–cervicogenital type–concordance
overall, noted by Steinau (2014) [14] and others, suggests
that, although not independent, the sites have differ-
ences in natural history (e.g. time to clearance). Here we
show that oral prevalence and oral–cervicogenital type-
concordance vary dramatically with age. This concor-
dance peaks for women ages 18–24, for whom nearly all
oral infections are type-concordant (Fig. 1). This may sug-
gest that many 18–24 year olds are experiencing their first
oral infection and that it is either caused by autoinocula-
tion from their genital infection or that both infections are
from the same sexual partner. That we do not see the same
pattern among ages 14–17 may be indicative of different
sexual norms and practices between the two groups, a
possibility that warrants further study. There is another
age span, 45–54, with both high overall prevalence and
high concordance. This may be indicative of a second
sexual debut or may reflect cohort differences.
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Fig. 4 Oral HPV prevalence with serotype-concordance for men and women. Prevalence is for 2009–10 and is given (a) by age and (b) race for
women and (c) by age and (d) by race for men. Serotype-concordance defined as an oral infection of type 6, 11, 16, or 18 with serum antibodies of
the same type
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Fig. 5 HPV seroprevalence and vaccination status for women ages 14–59. Seroprevalence is given a) by age and b) by race. The two bars in each
group represent 2007–08 and 2009–10 respectively. The shaded portion of the bar gives the fraction of those who are seropositive and also
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Table 2 Cerivcogenital HPV prevalence by genotype group and relative risk by vaccination status
Unvaccinated Vaccinated Relative risk
Age Genotypes N %+ S.E. N %+ S.E. RR 95% CI
All 244 17.5 2.7 233 20.1 3.5 1.1 0.7–1.8
14–17 Group 1 244 12.4 2.7 233 11.2 2.9 0.9 0.5–1.8
6, 11, 16, 18 244 4.5 1.7 233 1.0 0.5 0.2 0.1–0.8
All 448 57.7 3.4 241 56.9 3.5 1.0 0.8–1.2
18–24 Group 1 448 38.8 3.5 241 30.9 3.5 0.8 0.6–1.1
6, 11, 16, 18 448 16.6 2.5 241 2.5 0.7 0.2 0.1–0.3
Prevalence is by all, oncogenic (Group 1 genotypes), and vaccine genotypes for women ages 14–17 and 18–24 in 2009–12. Here, %+ denotes the weighted cervicogenital
HPV prevalence of the listed genotypes among the N people in the population. Bold relative risks intervals do not contain 1
Although discussion of HPV in the public health context
is often limited to mucosal types, other strains, includ-
ing those that cause common and plantar warts, infect
cutaneous tissue. It is possible that this tropism, that is
preference for certain kinds of tissue, may be relevant
within the mucosal types, with certain strains preferring
genital tissue and others preferring oral tissue. It is dif-
ficult to determine whether some strains—such as types
16, 62, 84—are commonly found at both sites because
of a lack of tropism, or simply because they are rela-
tively prevalent. However, the pattern of prevalence for
type 44 is consistent with a tropic preference for oral tis-
sue. More work will be needed to assess whether this and
other patterns—such as the higher prevalence of types
53, 54, and 61 among those with cervicogenital infections
than among those with oral infections—can be attributed
to tropism or are a reflection of cohort/timing patterns.
Tropism may be important when considering an evolu-
tionary perspective; changing sexual behaviors [36–39]
may have created evolutionary pressure, assuming some
level of genotype competition, favoring less tropic species.
Among those women who are seropositive for 6, 11,
16 or 18, prevalence of type-concordant cervicogenital
infections is low and decreases with age, as might be
expected since older individuals are more likely to have
already seroconverted during previous infections. For
racial demographics, seroprevalence more closely follows
the cerivcogenital rather than oral profile. This finding
may simply be a result of cervicogenital infections being
much more common than oral ones for women, but it
also raises the possibility that seroconversion may occur
more readily following cervical rather than oral infec-
tion. Combined with the different prevalence of serotype-
concordance for men and women (Fig. 4; the small racial
deviations in the overall patterns can be attributed to
low numbers and incomplete serotyping), this observa-
tion lends evidence to the theory that seroconversion
is strongly site-specific and occurs primarily at mucosal
epithelia. Cervicogenital infections appear to often lead
to seroconversion, which, based on the lack of sero–
oral type-concordance in women, may provide a defense
against oral infection. Men are less likely to seroconvert
from genital infections [17, 40–42], and so may be more
vulnerable to oral infections, resulting in a higher oral
prevalence.
Seroprevalence increases dramatically for 14–17 and
18–24 year old women over the period studied. Since the
aim of the vaccine is seroconversion, it is likely that this
increase is largely caused by the introduction of the vac-
cine (Fig. 5). Further, we want to determine the relative
risk of infection given vaccination. If one does not control
for age, overall cervicogenital prevalence and prevalence
of oncogenic types is higher in the vaccinated population
than in the unvaccinated, and prevalence of the genotypes
targeted by the vaccine is only slightly lower among the
vaccinated group. Because the vaccine is relatively new, it
may be being given to previously infected individuals. If
we restrict our attention to either 14–17 or 18–24 year
olds, as in Table 2, the relative risk for any and oncogenic
HPV drops to near 1, and that of the vaccine types drops to
about 0.2. Our results follow those reported byMarkowitz
(2013) [43], who found that, in NHANES 2007–10, preva-
lence of vaccine types was 12.6 % among unvaccinated
14–19 year olds but 3.1 % among those vaccinated. These
results suggests that the vaccine has been highly effective
at preventing infections by the targeted types. The current
data neither support nor refute the possibility that other
genotypes may move in to fill the niche left by the vaccine
genotypes.
Non-Hispanic black men and women have consistently
high prevalence at genital and oral sites and seropreva-
lence, which is consistent with previous work [14, 32].
The APC cohort trends for cervicogenital prevalence
(Fig. 6) suggest that this high prevalence relative to the
other racial groups has not changed much between the
1955 and 1980 birth cohorts and has, in fact, been
increasing since the 1980 birth cohort. Sexual assorta-
tivity patterns and other contributing factors may have
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Fig. 6 APC models of cervicogenital HPV prevalence among women, seroprevalence among women, and seroprevalence among men. Age-specific
prevalence and relative prevalence by birth cohort (relative to 50 % prevalence) by race for (a, b) cervicogenital prevalence, (c, d) female
seroprevalence, and (e, f) male seroprevalence
been relatively consistent between the 1970s and 1990s,
the times that people from these birth cohorts would
have been mostly sexually active. The relative prevalence
among women of all demographics decreased after the
1940s birth cohorts, the cohorts that experienced the sex-
ual revolution of the 1960s. For women of all races, cohort
effects for seroprevalence for women are dominated by
a large increase for those born after 1980, most likely
a consequence of vaccine-induced seroconversion. That
age–cohort models fit better than age–period is not sur-
prising, both as trends in STI prevalence tend to be driven
by cohort sexual norms and as the NHANES time span is
limited.
One strength of this study is the large sample size in
the NHANES survey, which allowed analysis at a relatively
fine demographic stratification. NHANES is the only pop-
ulation data source for oral infections and also allows for
analysis of multiple sites in one individual. Additionally,
the use of APC models allows for the analysis of tem-
poral trends in the data separate from the age effects.
Limitations of the NHANES data set include the rela-
tively limited time span, especially for oral infections, the
limited number of serotypes, and the lack of genital preva-
lence for men and anal prevalence for men and women.
Although, to our knowledge, no studies have investigated
seroconversion in women following anal infections, anal
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infections may play an important role in seroconversion in
men [16, 17, 42].
Conclusion
This study expands on the analysis by Steinau et al. [14]
to provide a deeper look at oral–cervicogenital type-
concordant infections. This paper is the first to ana-
lyze seroprevalence in NHANES after 2003–04 [32] and
the first to look at type-concordance between serum
antibodies and oral and genital infections. Our results
demonstrate that with increasing vaccination coverage,
seroprevalence alone is neither a good biomarker for oral
infections nor a sufficient one for genital infections in
women. Although not independent, infection status and
serum antibodies appear insufficiently correlated to be
predictive of each other. Conducting studies where sam-
pling is done at all three sites for both men and women
is paramount to fully characterize the natural history of
HPV and its transmission dynamics.
This study also provides further evidence that the
probability of serconversion from an infection may dif-
fer depending on which mucosal epithelium is infected.
Seroconversion from cervicogenital infection appears to
be common and may provide some measure of defense
against oral infections, based on the lack sero-oral concor-
dance in women. Previous studies show that men are less
likely to seroconvert from genital infections than women,
suggesting that they may thus be more vulnerable than
women to oral infection. Further, there is some indica-
tion that some genotypes are strongly tropic, preferring to
infect one site over another.
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